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ABSTRACT
OBJECTIVES
To provide the first report on the main outcomes 
from the prevalence and incidence rounds of a 
large pilot of routine primary high risk human 
papillomavirus (hrHPV) testing in England, compared 
with contemporaneous primary liquid based cytology 
screening.
DESIGN
Observational study.
SETTING
The English Cervical Screening Programme.
PARTICIPANTS
578 547 women undergoing cervical screening in 
primary care between May 2013 and December 2014, 
with follow-up until May 2017; 183 970 (32%) were 
screened with hrHPV testing.
INTERVENTIONS
Routine cervical screening with hrHPV testing with 
liquid based cytology triage and two early recalls 
for women who were hrHPV positive and cytology 
negative, following the national screening age and 
interval recommendations.
MAIN OUTCOME MEASURES
Frequency of referral for a colposcopy; adherence 
to early recall; and relative detection of cervical 
intraepithelial neoplasia grade 2 or worse from hrHPV 
testing compared with liquid based cytology in two 
consecutive screening rounds.
RESULTS
Baseline hrHPV testing and early recall required 
approximately 80% more colposcopies, (adjusted 
odds ratio 1.77, 95% confidence interval 1.73 to 
1.82), but detected substantially more cervical 
intraepithelial neoplasia than liquid based cytology 
(1.49 for cervical intraepithelial neoplasia grade 2 or 
worse, 1.43 to 1.55; 1.44 for cervical intraepithelial 
neoplasia grade 3 or worse, 1.36 to 1.51) and for 
cervical cancer (1.27, 0.99 to 1.63). Attendance at 
early recall and colposcopy referral were 80% and 
95%, respectively. At the incidence screen, the 33 506 
women screened with hrHPV testing had substantially 
less cervical intraepithelial neoplasia grade 3 or worse 
than the 77 017 women screened with liquid based 
cytology (0.14, 0.09 to 0.23).
CONCLUSIONS
In England, routine primary hrHPV screening increased 
the detection of cervical intraepithelial neoplasia 
grade 3 or worse and cervical cancer by approximately 
40% and 30%, respectively, compared with liquid 
based cytology. The very low incidence of cervical 
intraepithelial neoplasia grade 3 or worse after three 
years supports extending the screening interval.
Introduction
Randomised trials have shown that cervical screening 
for high risk human papillomavirus (hrHPV) achieves 
greater sensitivity than cytology in the detection 
of cervical intraepithelial neoplasia and greater 
protection against cervical cancer.1-5 Because of 
the enhanced sensitivity, screening intervals can 
be safely extended.5  6 However, hrHPV testing has 
reduced specificity compared with cytology, due to 
the high prevalence of hrHPV.7 Excessive referral for a 
colposcopy can be mitigated by triage of positive hrHPV 
test results by using reflex liquid based cytology. Most 
women who are hrHPV positive who undergo reflex 
cytology will have a normal result (cytology negative), 
however, this group of women remain at increased risk 
either because of underlying disease not detected by 
cytology, or because of an increased risk of incident 
disease.5 8 Alternative strategies for management 
for this group are either referral for a colposcopy for 
women who are at greatest risk of underlying disease by 
virtue of being human papillomavirus genotype 16/18 
positive, or to defer a colposcopy anticipating evidence 
of clearance of the hrHPV infection (which will occur 
in around 40% by 12 months),9 thus allowing these 
women to be returned safely to routine recall.
WHAT IS ALREADY KNOWN ON THIS TOPIC
More than 15 years of research with randomised controlled trials have 
produced a strong evidence base supporting the superiority of high risk human 
papillomavirus (hrHPV) testing for detection of cervical intraepithelial neoplasia 
grade 2 or worse compared with the current standard of liquid based cytology
Several countries have updated their screening guidelines and are switching 
from primary liquid based cytology with hrHPV triage to primary hrHPV testing 
with liquid based cytology triage
NHS England and Public Health England are working toward a national roll-out by 
the end of 2019
WHAT THIS STUDY ADDS
The pilot confirmed that prior screening with hrHPV testing is associated with a 
much lower incidence of high grade cervical intraepithelial neoplasia compared 
with liquid based cytology
Cervical screening intervals can be safely extended
hrHPV testing for cervical screening is practicable in England
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The UK National Screening Committee recommended 
a switch to hrHPV primary screening in January 
2016. NHS England and Public Health England are 
now working towards a national roll-out by the end 
of 2019. In support of the anticipated roll-out, a 
pilot was established in 2013 involving a group of 
screening laboratories in the NHS Cervical Screening 
Programme in England.10 11 Conversion to primary 
hrHPV was partial, which allowed for comparison with 
contemporaneous primary liquid based cytology. This 
recognised the importance of implementing primary 
hrHPV screening in a controlled manner, enabling 
evaluation of a protocol with respect to practicability, 
acceptability, and cost effectiveness. The value of the 
pilot in terms of learning was further enhanced by a 
prespecified variation in protocol, ahead of a national 
roll-out.
Here, we studied baseline referral for a colposcopy 
and the extent of additional colposcopy referrals as a 
result of early recall of women who were hrHPV positive 
and cytology negative; adherence to early recall; the 
sensitivity of hrHPV testing in the prevalence round 
and the incidence of high grade cervical intraepithelial 
neoplasia among women who were hrHPV negative at 
three years.
Methods
Six NHS laboratories had partially converted to 
primary hrHPV testing between May and August 
2013. These laboratories in Bristol, Liverpool, 
Manchester, Norwich, Northwick Park (West London), 
and Sheffield represent approximately 13% of the 
Cervical Screening Programme. Conversion, which 
involved around one third of screening samples, was 
population based. Distribution of primary hrHPV 
testing was based on clusters of general practices 
and was not subject to random allocation. Rather, 
allocation to liquid based cytology or hrHPV testing 
was a consequence of practical considerations such 
as maintaining one management protocol for each 
colposcopy unit, whereby colposcopy units often serve 
defined administrative clusters. Samples from women 
who were screened after a routine invitation were 
collected in primary care in either ThinPrep (Hologic, 
Marlborough, MA) or SurePath (Beckton Dickinson, 
Sparks, MD) liquid based cytology media, regardless 
of whether liquid based cytology or hrHPV was the 
primary screening test. hrHPV testing was performed 
with either the Cobas 4800 (Roche, Rotkreuz, 
Switzerland, or Branchburg, NJ), RealTime (Abbott, 
Wiesbaden, Germany), APTIMA (Hologic, Manchester, 
UK), or, to a limited degree, Hybrid Capture 2 (Qiagen, 
Gaithersburg, MD) assays. Each laboratory used a 
unique combination of liquid based cytology medium 
and hrHPV assay. All screening tests have been 
approved for use in the English Cervical Screening 
Programme following the official validation protocols.
The pilot adhered to the nationally recommended 
age range (25-64) and screening intervals (three years 
for women aged <50 and five years thereafter) for both 
screening tests. In women screened with hrHPV testing, 
cytology was not blinded to the hrHPV test result. 
Women were immediately referred for a colposcopy 
if their hrHPV test was positive and cytology showed 
any grade of abnormality. Women who were hrHPV 
positive with negative cytology were recommended 
for early recall at 12 months, at which point they were 
referred for a colposcopy if they remained persistently 
hrHPV positive and had developed any cytological 
abnormalities. Three laboratories referred women with 
persistently negative cytology at 12 months if their 
samples showed persistent infection with HPV 16/18. 
Other women who were hrHPV positive and cytology 
negative were offered further early recall at 24 months, 
and were referred for a colposcopy if they showed a 
persistent hrHPV infection regardless of their cytology. 
Women screened with cytology were recommended 
for a colposcopy if their cytology showed high grade 
abnormalities consistent with high grade squamous 
intraepithelial lesions in Bethesda 2001 terminology 
or low grade abnormalities consistent with either 
atypical squamous cells of undetermined significance 
(ASCUS) or low grade squamous intraepithelial 
lesions combined with a positive reflex test for hrHPV. 
Cytological glandular abnormalities were classified 
among high grade squamous intraepithelial lesions. 
Women not referred to colposcopy or early recall were 
routinely recalled at three or five years.
Screening was conducted in primary care, and 
training in relation to hrHPV based screening was 
provided. The laboratories routinely monitored 
compliance with referral for a colposcopy, and there 
was a safety net in place for women who did not 
attend. Colposcopy was conducted according to 
national clinical practice guidelines. All laboratories 
and colposcopy clinics took part in the national quality 
assurance programmes.
Data sources and linkage
We retrieved records for screening samples taken 
by general practitioners and information on the 
associated referrals for a colposcopy from the pilot 
laboratories’ information systems. The data were 
collated, processed, and analysed centrally at Queen 
Mary University of London. For the present report, 
complete data were available until 31 May 2017. We 
linked tests from the same woman by using unique 
English NHS numbers. For the period starting two 
years preceding the pilot, the date of sample and 
recommendation were collected. We excluded index 
samples that had been preceded by another within 
the prior two years, because they were probably not 
taken for primary screening. We also excluded index 
samples if their management code identified the 
sample to have been taken as follow-up or at the time 
of colposcopy. Episodes started with the first (index) 
screening test and were closed depending on this test’s 
outcome and any subsequent tests (supplementary 
material). If an initial inadequate test (0.3% with 
hrHPV testing, and 2.3% with liquid based cytology) 
was followed by a valid test, we used the result of the 
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latter for analyses. The first episode for each woman 
was considered the prevalence episode with respect to 
the initiation of the pilot; subsequent episodes were 
incidence episodes.
Statistical analysis
We included all women aged 24-64 because the 
initial screening invitation is sent six months before a 
woman turns 25 years. We based the main analyses on 
prevalence episodes that had started by 31 December 
2014 to provide complete cumulative data including 
early recall outcomes. These women had 29 months 
or more of follow-up in the available data. A subset of 
these women, those with screening samples processed 
at three laboratories that used human papillomavirus 
genotyping for management of women at the 12 
month early recall, provided human papillomavirus 
genotyping data. We included incidence episodes if 
women aged 24-46 at the prevalence episode had been 
directed to routine recall in three years.
We tested differences in the distribution of sample 
characteristics at the index test of the prevalence 
round with χ2. We defined a positive screening test 
result as a result with a known screening and triage 
test result that required further clinical management 
according to the recommended protocol. We calculated 
odds ratios and their 95% confidence intervals for 
differences between hrHPV and cytology screening 
with logistic regression, and adjusted for the woman’s 
age, processing laboratory, and decile of index of 
multiple deprivation. The robustness of the results for 
the two main outcomes, the number of colposcopies 
and cervical intraepithelial neoplasia grade 2 or 
worse, was additionally studied by applying a Mantel-
Haenszel test to 240 strata defined by laboratory (six 
sites), index of multiple deprivation (five quintiles) and 
five year age group (eight groups: 24-29, 30-34, 35-39, 
40-44, 45-49, 50-54, 55-59, and 60-64). We based the 
index of multiple deprivation on the woman’s postcode 
at the time of her index sample (supplementary 
material). We excluded 9689 (1.6%) from the total of 
578 547 women entering the pilot until 31 December 
2014 for having an unknown postcode.
All data management and statistical analyses were 
undertaken with R version 3.2.4 and Oracle SQL 
Developer version 4.0.2.
Patient and public involvement
Neither patients nor the public were involved in the 
management of this study. A parallel investigation 
on the psychological consequences of hrHPV testing 
compared with liquid based cytology screening 
embedded into the pilot will report its findings 
separately.12
Results
Baseline (prevalence) screening round and 
compliance with early recall
This on-going pilot included 1 532 908 women 
screened in the prevalence round until 31 May 2017 
(supplementary table 1). The distribution by age was: 
297 843 (19%) were aged 24-29, 850 088 (55%) 30-
49, and 384 977 (25%) 50-64. Of these, 442 174 
(29%) women were screened with hrHPV testing and 
1 090 734 (71%) were screened with liquid based 
cytology. Overall recruitment between laboratories 
varied from 139 211 to 544 865, and 875 641 (57%) 
were from the most deprived areas (deciles 1-5 of the 
index of multiple deprivation). Table 1 shows that by 31 
December 2014, 578 547 women had been screened, 
with a similar age and deprivation distribution as that 
across the entire pilot. Women screened with hrHPV 
testing were more likely to be from more affluent areas, 
and were marginally, but statistically significantly, 
older (χ2<0.0001). Additionally, the proportion of 
conversion to hrHPV screening differed by laboratory 
(χ2<0.0001).
Figures 1A and 1B show, respectively, the per 
protocol detection of cervical intraepithelial neoplasia 
down the protocol pathway, for primary hrHPV and 
primary cytology (detailed outcomes including those 
outside of the protocol are reported in supplementary 
fig 1 and  2). Table 1 shows that hrHPV testing was 
positive in 12.7% of all screened women; 28.0% below 
age 30, 10.5% aged 30-49, and 5.6% aged 50-64 
(table 2). Table 3 shows that about one third of hrHPV 
positive women were HPV 16/18 positive.
hrHPV positive/cytology positive
(690 CIN2+)
Early recall at 12 months
2015
hrHPV positive
(261 CIN2+)
2186
hrHPV negative
1140
hrHPV positive/cytology negative
(108 CIN2+)
5300
hrHPV negative
5482
12 830
Early recall at 24 months
hrHPV positive/cytology positive
(3060 CIN2+)
Index test
7728
hrHPV positive/cytology negative
A
B
hrHPV negative
183 970
160 464 15 603
3326
Index test
High grade
abnormal cytology
(4365 CIN2+)
5492
Low grade abnormal
cytology/hrHPV positive
(1567 CIN2+)
9629
Low grade abnormal
cytology/hrHPV negative
6923
Cytology negative
369 688
394 579
Fig 1 | Flow diagram for prevalence episodes that started by 31 December 2014 
including outcomes from per protocol follow-up until 31 May 2017 for women screened 
with high risk human papillomavirus (hrHPV) testing (A) and liquid based cytology (LBC) 
(B). CIN2+=cervical intraepithelial neoplasia grade 2 or worse
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Table 1 | Comparison of populations and outcomes for high risk human papillomavirus (hrHPV) testing versus liquid based cytology (LBC) in the 
baseline (prevalence) screening round. Values are numbers (percentages) unless stated otherwise
Characteristic hrHPV LBC
Odds ratio for hrHPV testing v LBC (95% CI)
Unadjusted Adjusted*
Total 183 970 (100) 394 577 (100) NA NA
Age at screening (years):
 24-29 35 085 (19) 75 847 (19) NA NA
 30-49 105 365 (57) 226 034 (57) NA NA
 50-64 43 520 (24) 92 696 (23) NA NA
IMD deciles at screening:
 1-5 (most deprived) 93 001 (51) 229 576 (58) NA NA
 6-10 (least deprived) 90 969 (49) 165 001 (42) NA NA
Procedures (% screened)†:
  Positive screening test outcomes requiring additional testing 23 331 (12.7)‡ 15 121 (3.8)§ 3.64 (3.57 to 3.72) 3.90 (3.81 to 3.98)
 Immediate referrals¶ 7724 (4.2) 15 117 (3.8) 1.10 (1.07 to 1.13) 1.14 (1.11 to 1.17)
 Referrals after repeated testing¶ 5070 (2.8) NR NR NR
 Total referral** 13 010 (7.1) 18 205 (4.6) 1.57 (1.54 to 1.61) 1.61 (1.57 to 1.65)
 Total colposcopies** 12 559 (6.8) 16 378 (4.2) 1.69 (1.65 to 1.73) 1.77 (1.73 to 1.82)
Histological outcomes, after  immediate referral (% screened)†¶:
 CIN2+ 3060 (1.7) 5932 (1.5) 1.11 (1.06 to 1.16) 1.12 (1.07 to 1.17)
 CIN3+ 1939 (1.1) 3753 (1.0) 1.11 (1.05 to 1.17) 1.12 (1.06 to 1.19)
 Cervical cancer 89 (0.1) 167 (0.0) 1.14 (0.88 to 1.48) 1.14 (0.88 to 1.48)
Histological outcomes including immediate referral and early recall (% screened)† ††:
 Normal biopsy 6284 (3.4) 7126 (1.8) 1.92 (1.86 to 1.99) 1.98 (1.91 to 2.05)
 CIN1 2039 (1.1) 2780 (0.7) 1.58 (1.49 to 1.67) 1.71 (1.62 to 1.82)
 CIN2+ 4156 (2.3) 6113 (1.6) 1.47 (1.41 to 1.53) 1.49 (1.43 to 1.55)
 CIN3+ 2521 (1.4) 3833 (1.0) 1.42 (1.35 to 1.49) 1.44 (1.36 to 1.51)
 Cervical cancer 101 (0.1) 170 (0.0) 1.27 (1.00 to 1.63) 1.27 (0.99 to 1.63)
NA=not applicable; IMD=index of multiple deprivation; NR=not relevant; CIN2+=cervical intraepithelial neoplasia grade 2 or worse; CIN3+=cervical intraepithelial neoplasia grade 3 or worse; 
CIN1=cervical intraepithelial neoplasia grade 1.
*Adjusted for age (years), IMD decile, and laboratory.
†See supplementary figure 1A for hrHPV and 1B for LBC.
‡hrHPV positive with a known cytological outcome.
§hrHPV positive low grade abnormal cytology or high grade abnormal cytology regardless of the hrHPV status.
¶Per protocol, in women with a record of referral to the specific type of follow-up (see supplementary figure 1A). 
**Counted as one per woman, including referrals or colposcopies conforming to the screening recommendations and colposcopies in women with screening test results for which the screening 
recommendations did not include a referral for colposcopy.
††Includes biopsies taken per protocol (colposcopy after immediate referral or after early recall at 12 and 24 months), and biopsies taken outside of the protocol (see supplementary figure 1).
Table 2 | Screening outcomes in the baseline (prevalence) screening round for high risk human papillomavirus (hrHPV) testing versus liquid based 
cytology (LBC), by age group
Outcome
Age group (years)
Total24-29 30-49 50-64
hrHPV (%)
Number 35 085 (100) 105 365 (100) 43 520 (100) 183 970 (100)
Positive screening test 9836 (28.0) 11 047 (10.5) 2448 (5.6) 23 331 (12.7)
Immediate referral for colposcopy 3795 (10.8) 3340 (3.2) 589 (1.4) 7724 (4.2)
Colposcopies 5826 (16.6) 5561 (5.3) 1172 (2.7) 12 559 (6.8)
CIN2+ 2299 (6.6) 1638 (1.6) 219 (0.5) 4156 (2.3)
CIN3+ 1403 (4.0) 1000 (0.9) 118 (0.3) 2521 (1.4)
LBC (%)
Number 75 847 (100) 226 034 (100) 92 696 (100) 394 577 (100)
Positive screening test 7309 (9.6) 6678 (3.0) 1134 (1.2) 15 121 (3.8)
Immediate referral for colposcopy 7309 (9.6) 6675 (3.0) 1133 (1.2) 15 117 (3.8)
Colposcopies 7606 (10.0) 7436 (3.3) 1336 (1.4) 16 378 (4.2)
CIN2+ 3319 (4.4) 2497 (1.1) 297 (0.3) 6113 (1.5)
CIN3+ 2103 (2.8) 1555 (0.7) 175 (0.2) 3833 (1.0)
Unadjusted odds ratio for hrHPV v LBC (95% CI)
Positive screening test 3.65 (3.53 to 3.78) 3.85 (3.73 to 3.97) 4.81 (4.48 to 5.17) 3.64 (3.57 to 3.72)
Immediate referral for colposcopy 1.14 (1.09 to 1.19) 1.08 (1.03 to 1.12) 1.11 (1.00 to 1.23) 1.10 (1.07 to 1.13)
Colposcopies 1.79 (1.72 to 1.85) 1.64 (1.58 to 1.70) 1.89 (1.75 to 2.05) 1.69 (1.65 to 1.73)
CIN2+ 1.53 (1.45 to 1.62) 1.41 (1.33 to 1.51) 1.57 (1.32 to 1.87) 1.49 (1.43 to 1.55)
CIN3+ 1.46 (1.36 to 1.56) 1.38 (1.28 to 1.50) 1.44 (1.14 to 1.82) 1.44 (1.36 to 1.51)
Adjusted odds ratio for hrHPV v LBC (95% CI)
Positive screening test 3.60 (3.48 to 3.73) 4.02 (3.90 to 4.16) 5.12 (4.76 to 5.51) 3.90 (3.81 to 3.98)
Immediate referral for colposcopy 1.13 (1.08 to 1.18) 1.13 (1.09 to 1.18) 1.18 (1.07 to 1.31) 1.14 (1.11 to 1.17)
Colposcopies 1.77 (1.70 to 1.84) 1.73 (1.67 to 1.79) 2.07 (1.91 to 2.25) 1.77 (1.73 to 1.82)
CIN2+ 1.50 (1.42 to 1.59) 1.45 (1.36 to 1.55) 1.67 (1.40 to 2.00) 1.49 (1.43 to 1.55)
CIN3+ 1.44 (1.35 to 1.55) 1.42 (1.31 to 1.54) 1.54 (1.22 to 1.96) 1.44 (1.36 to 1.51)
See supplementary figure 1A for hrHPV testing and 1B for LBC details.
CIN2+=cervical intraepithelial neoplasia grade 2 or worse; CIN3+=cervical intraepithelial neoplasia grade 3 or worse
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Figure 1B shows that, among women screened with 
cytology, 4.0% had low grade abnormal and 1.4% had 
high grade abnormal cytology. After hrHPV triage of 
low grade cytological abnormalities, 3.8% (table 1) of 
all screened women had abnormalities that required 
colposcopy referral: 9.6% aged 24-29, 3.0% aged 30-
49, and 1.2% aged 50-64 (table 2). Table 2 shows that, 
by comparison, after hrHPV screening, 4.2% of women 
were referred for colposcopy immediately because of 
concurrent positive cytology; 10.8% aged 24-29, 3.2% 
aged 30-49, and 1.4% aged 50-64. Table 3 shows that, 
compared with women with other high risk infections, 
women with HPV 16/18 infections were twice as likely 
to have concurrent positive cytology (44% v 27%, 
adjusted odds ratio 2.02, 95% confidence interval 
1.89 to 2.17). Among the primary hrHPV positives with 
negative cytology, 2.8% were referred after early recall 
at 12 and 24 months, bringing the total proportion of 
women referred per protocol to 7.0%. Table 4 shows 
that among women who were hrHPV positive and 
cytology negative and recommended for early recall 
at 12 months, 83% attended, and amongst women 
with a persistent hrHPV positive and cytology negative 
test result who were recommended for retesting 
at 24 months, 76% so far attended. Attendance at 
colposcopy after immediate referral was 98% after 
screening with hrHPV and 94% after screening with 
cytology. It remained high after early recall at both 12 
and 24 months, 96% and 89%, respectively.
Table 3 shows that by the 12 month early recall, 
women with normal index cytology were less likely to 
become hrHPV negative if they were infected with HPV 
16/18 compared with other genotypes ( 32% v 45%, 
adjusted odds ratio 0.58, 95% confidence interval 0.53 
to 0.64). By 24 months, an additional 35% of women 
who were hrHPV positive with persistently negative 
cytology had cleared their infections.
Table 1 shows that cervical intraepithelial neoplasia 
grade 2 or worse was detected in 4156 (2.26%) women 
and cervical intraepithelial neoplasia grade 3 or 
worse in 2521 (1.37%) women screened with hrHPV 
testing. Approximately one in four of these lesions 
were detected after early recall of women who were 
HPV positive and cytology negative. Of the 101 women 
diagnosed with cervical cancer, 89 (88%) diagnoses 
were made after an immediate referral for colposcopy, 
suggesting that early recall after negative cytology was 
a safe strategy. Table 2 shows that detection of cervical 
intraepithelial neoplasia grade 2 or worse was strongly 
dependent on age, with the highest detection among 
women under 30 (6.6%), fourfold higher than at 30-
49 (1.6%), and more than 10 times the detection at 50 
or over (0.5%). Of all detected cervical intraepithelial 
neoplasia grade 2 or worse, 55% (2299/4156) were 
detected at 24-29, 39% (1638/4156) at 30-49, and 
5% (219/4156) at 50-64 years of age. Among women 
screened with cytology, 3833 (1.0%) had cervical 
intraepithelial neoplasia grade 3 or worse. Cervical 
intraepithelial neoplasia grade 2 or worse was 
diagnosed in 6113 (1.5%) women, with 4.4% at 24-
29, 1.1% at 30-49, and 0.3% at 50-64.
Positive predictive value of referral to colposcopy
Table 4 shows that after immediate referral of 
women who were hrHPV positive and cytology 
positive, cervical intraepithelial neoplasia grade 
2 or worse was detected in 41% (the positive 
predictive value was 19% for low grade and 87% 
for high grade cytology). After referral at 12 month 
early recall, cervical intraepithelial neoplasia 
grade 2 or worse was detected in 36% if cytology 
had become abnormal but only 13% if cytology 
remained negative with genotype 16/18 infection. At 
24 month early recall, among all women who were 
persistently hrHPV positive, the positive predictive 
value of colposcopy establishing a diagnosis of 
cervical intraepithelial neoplasia grade 2 or worse 
was 14%. Among women screened with cytology, 
the positive predictive value was 86% for cervical 
intraepithelial neoplasia grade 2 or worse following 
high grade, and 17% following low grade cytology, 
giving a combined positive predictive value of 42%. 
On average, the positive predictive value for cervical 
intraepithelial neoplasia grade 2 or worse was 33% 
(4156/12 559) for colposcopies in hrHPV testing and 
37% (6113/16 378) for colposcopies in liquid based 
Table 3 | Screening outcomes by the infecting human papillomavirus (HPV) genotype in three laboratories that managed women according to genotype 
at 12 month early recall
Outcome
HPV 16/18 Other HPV Odds rato for HPV 16/18 v other HPV (95% CI)
No (%) Total No (%) Total Unadjusted Adjusted
No at baseline
Screened 5207 (4) 127 238 10 890 (9) 127 238 NA NA
Positive cytology 2293 (44) 5207 2994 (27) 10 890 2.08 (1.94 to 2.22) 2.02 (1.89 to 2.17)
Persistence of hrHPV infection
Negative cytology at baseline, persistence at 12 months 1639 (68) 2398 3624 (55) 6566 1.75 (1.58 to 1.93) 1.72 (1.56 to 1.90)*
Negative cytology at 12 months, persistence at 24 months NA NA 1368 (65) 2091 NA NA
Colposcopy outcomes
PPV for CIN2+ at baseline, positive cytology 1295 (57) 2254 840 (29) 2909 3.33 (2.96 to 3.73) 3.12 (2.78 to 3.52)
PPV for CIN2+ at 12 months, positive cytology 252 (48) 528 221 (27) 825 2.50 (1.98 to 3.14) 2.28 (1.80 to 2.89)
PPV for CIN2+ at 12 months, negative cytology 103 (13) 789 NA NA NA NA
PPV for CIN2+ at 24 months, persistent hrHPV+ NA NA 117 (10) 1144 NA NA
See supplementary figure 1A for hrHPV testing details.
NA=not applicable; hrHPV=high risk human papillomavirus; PPV=positive predictive value; CIN2+= cervical intraepithelial neoplasia grade 2 or worse.
*For clearance (=1-persistence), the unadjusted odds ratio was 0.57 (95% CI 0.52 to 0.63), and the adjusted odds ratio was 0.58 (95% CI 0.53 to 0.64).
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cytology screening (adjusted odds ratio 0.78, 95% 
confidence interval 0.74 to 0.82; data not shown).
Table 3 shows that about 60% (1650/2828) of all 
detected cervical intraepithelial neoplasia grade 2 
or worse were associated with HPV 16/18 infections 
(of which 94%, 1547/1650, of women had positive 
cytology either at baseline or at the 12 month early 
recall). After adjustment for key variables, the odds of 
a cervical intraepithelial neoplasia grade 2 or worse 
lesion diagnosed at colposcopy after abnormal index 
cytology were three times as high for HPV 16/18 
infections than for other high risk genotypes (positive 
predictive value for cervical intraepithelial neoplasia 
grade 2 or worse 57% v 29%, adjusted odds ratio 
3.12, 95% confidence interval 2.78 to 3.52). This 
difference remained at 12 month recall in women 
with persistent infections and incident positive 
cytology (48% v 27%, 2.28, 1.80 to 2.89). In women 
with negative cytology despite persistent HPV 16/18 
infections, the positive predictive value of colposcopy 
at 12 months was far lower (13%) and among women 
with any persistent infection with other hrHPV 
genotypes at 24 months, the positive predictive value 
was 10%, and just 6% (data not shown) if cytology 
was negative.
Comparison of hrHPV testing with cytology in the 
prevalence round
Table 1 shows that women screened with hrHPV 
testing were more likely to have a positive screening 
test that required further management (adjusted odds 
ratio 3.90, 95% confidence interval 3.81 to 3.98), and 
were also more likely to be referred for colposcopy 
immediately after screening (1.14, 1.11 to 1.17). 
The proportion of abnormal reflex cytology was 33% 
(7728/23 331, fig 1A). hrHPV testing led to a higher 
detection of cervical intraepithelial neoplasia grade 
2 or worse at immediate referral (1.12 for cervical 
intraepithelial neoplasia grade 2 or worse, 1.07 to 
1.17; 1.12 for cervical intraepithelial neoplasia grade 
3 or worse, 1.06 to 1.19) and for cervical cancer (1.14, 
0.88 to 1.48); this increase became significant with 
a larger number of screened women (adjusted odds 
ratio 1.21, 95% confidence interval 1.02 to 1.43; 
supplementary table 2).
Table 1 shows that when referrals after early recall 
at 12 and 24 months were included, the proportion 
of women with a colposcopy was significantly higher 
for hrHPV testing than for cytology (adjusted odds 
ratio 1.77, 95% confidence interval 1.73 to 1.82). The 
Mantel-Haenszel estimate controlling for all 240 strata 
was very similar, 1.79 (95% confidence interval 1.75 
to 1.84). Also, the detection of cervical intraepithelial 
neoplasia was significantly higher with hrHPV testing. 
Compared with cytology, adjusted odds ratio for 
cervical intraepithelial neoplasia grade 2 or worse 
was 1.49 (95% confidence interval 1.43 to 1.55), for 
cervical intraepithelial neoplasia grade 3 or worse 
was 1.44 (1.36 to 1.51), and for cervical cancer 1.27 
(0.99 to 1.63); also this difference reached statistical 
significance with a larger number of screened 
women, 1.32 (95% confidence interval 1.12 to 1.55; 
supplementary table 2). hrHPV testing did, however, 
involve more biopsies without an abnormality (adjusted 
odds ratio 1.98, 95% confidence interval 1.91 to 2.05) 
or with at most cervical intraepithelial neoplasia grade 
1 (1.71, 1.62 to 1.82). The Mantel-Haenszel estimate 
for the detection of cervical intraepithelial neoplasia 
grade 2 or worse was consistent with the primary 
analysis, with an odds ratio controlling for 240 strata 
of 1.50 (95% confidence interval 1.44 to 1.57).
Incidence screening round
By the end of 2014, 354 715 women aged 24-46 had 
been referred back to routine three year recall. To 
date, 122 032 (34%) have attended for a new primary 
screening test; 33% of the women were screened with 
hrHPV testing and 35% screened with cytology in the 
prevalence round (odds ratio for attendance adjusted 
for key variables 0.86, 95% confidence interval 0.85 to 
0.87). Attendance at the incidence round was slightly 
higher in less deprived areas (adjusted odds ratio per 
decile of the index of multiple deprivation 1.03, 95% 
confidence interval 1.03 to 1.03).
Table 5 shows the outcomes for 110 523 women 
who were rescreened with the same test in the 
Table 4 | Compliance with per protocol referrals for colposcopy and early recall, and the associated positive predictive values (PPV) for cervical 
intraepithelial neoplasia grade 2 or worse (CIN2+)
Referral
hrHPV testing Liquid based cytology
No referred No attended (%) CIN2+ (PPV) No referred No attended (%) CIN2+ (PPV)
Immediate referral for colposcopy 7724 7542 (98) 3060 (41)* 15 117 14 250 (94) High grade cytology: 4365 (86)†
Low grade abnormal: 1567 (17)‡
Combined: 5932 (42)
Early recall at 12 months 15 425 12 830 (83) NA NA NA NA
Colposcopy after early recall at 12 months 2914 2786 (96) Negative cytology: 108 (13)§
Positive cytology: 690 (36)¶
NA NA NA
Early recall at 24 months 4399 3326 (76) NA NA NA NA
Colposcopy after early recall at 24 months 2156 1912 (89) 261 (14) NA NA NA
hrHPV=high risk human papillomavirus; NA=not applicable.
See supplementary figure 1A for hrHPV testing and 1B for LBC details.
*The PPV was 87% (2115/2438) for women with concurrent high grade cytology and 19% (945/5104) for women with concurrent low grade cytology.
†PPV calculated for 5084 women with high grade cytology who attended colposcopy.
‡PPV calculated for 9166 women with low grade cytology and a positive hrHPV triage test result who attended colposcopy.
§PPV calculated for 849 women who were hrHPV positive with negative cytology at 12 month early recall who attended colposcopy.
¶Positive cytology: low grade abnormalities or worse. PPV calculated for 1937 women with hrHPV who had positive cytology at 12 month early recall who attended colposcopy.
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incidence round at three years. Most women had the 
same screening test as in the prevalence round. Among 
the 33 506 women screened with hrHPV testing in both 
rounds, 2271 (6.8%) had a positive screening test, just 
over half that seen in the prevalence round, with 495 
(1.5%) immediately referred for colposcopy. Among 
the 77 017 women screened with cytology in both 
screening rounds, these proportions were 2.5% and 
2.4%, respectively. Detection of cervical intraepithelial 
neoplasia grade 2 or worse was substantially lower in 
women screened with hrHPV testing (0.2% v 0.7% for 
cervical intraepithelial neoplasia grade 2 or worse, 
adjusted odds ratio 0.29, 95% confidence interval 
0.22 to 0.38; 0.1% v 0.5% for cervical intraepithelial 
neoplasia grade 3 or worse, adjusted odds ratio 0.14, 
95% confidence interval 0.09 to 0.23).
Discussion
This pilot confirmed the findings of randomised trials 
and showed increased sensitivity for primary screening 
with hrHPV.1-5 hrHPV compared with liquid based 
cytology detected 50% more cervical intraepithelial 
neoplasia grade 2 or worse, 40% more cervical 
intraepithelial neoplasia grade 3 or worse, and 30% 
more cervical cancer in the prevalence round. A quarter 
of cervical intraepithelial neoplasia grade 2 or worse 
was detected after early recall in women with negative 
cytology, which clearly shows the added sensitivity of 
hrHPV testing seen across the entire age range. This 
increased sensitivity is reflected in the remarkably low 
detection of cervical intraepithelial neoplasia grade 
2 or worse among women who were hrHPV negative 
when rescreened at three years, being only 29% and 
14% of that after a prevalence round negative liquid 
based cytology, for cervical intraepithelial neoplasia 
grade 2 or worse and cervical intraepithelial neoplasia 
grade 3 or worse, respectively.
Our data suggest that the lower incidence of cervical 
cancer after a normal screening test reported from 
the randomised trials will be realised in the pilot.3 In 
the trials, this incidence was decreased by 70% up to 
eight years after screening (relative detection rate for 
hrHPV compared with cytology 0.30, 95% confidence 
interval 0.15 to 0.60).3 At present, 2500 women are 
diagnosed with cervical cancer each year in England, 
with a quarter diagnosed after negative cytology.13 
Screening with hrHPV testing would translate to 
400-500 fewer cases, or an about 20% decrease in 
the overall incidence, once hrHPV screening is rolled 
out nationally.14 The lower incidence of cervical 
intraepithelial neoplasia grade 3 or worse and cervical 
cancer at present screening intervals would strongly 
support the safety of extending the intervals to at least 
five years without increasing the risk of potentially life 
threatening disease.3 6 The English Cervical Screening 
Programme, started in 1988, has been responsible 
for a decrease of 30% in cervical cancer incidence, 
but since 2002 this has plateaued. We would expect 
a further decrease after implementation of primary 
hrHPV screening when combined with the NHS HPV 
vaccination programme, which began in 2008.
Cytology triage of women who were hrHPV positive 
resulted in 7% of those screened being referred for a 
colposcopy, 4% immediately and 3% after early recall. 
Referral was high in women under 30, with almost 
17% having a colposcopy, compared with 5% of those 
aged 30-49 and 3% of those aged 50-64. The increased 
demand for a colposcopy for women who were hrHPV 
positive and cytology negative is likely temporary. 
Our preliminary data from the incidence round show 
a halving of hrHPV positive rates compared with the 
prevalence round, as well as a reduction in cytological 
abnormalities. The referral rate will decrease further 
when younger birth cohorts enter the NHS Cervical 
Screening Programme in 2020 because over 80% of 
them will have been vaccinated against HPV 16/18.15
hrHPV positive with negative cytology appeared to 
be a safe basis on which to defer repeated testing of 
women who were hrHPV positive.16 The additional 
cases of cervical cancer diagnosed after early recall of 
women who were hrHPV positive and cytology negative 
at 12 and 24 months also support the relative safety of 
the implemented triage strategy, since these women 
would have been deferred to a routine recall at 36 or 
60 months had their primary screening test remained 
liquid based cytology.
Table 5 | Screening outcomes in the incidence round, by combination of tests in the prevalence and incidence screening rounds, among women aged 
24-46 who were referred to routine recall at three years in the prevalence round
Outcome
Prevalence and incidence round (%)* Odds ratio for hrHPV testing v LBC (95% CI)
hrHPV LBC Unadjusted Adjusted†
Incident episodes:
 Total 33 506 (100.0) 77 017 (100.0) NA NA
 Negative in the prevalence round 33 407 (99.7) 77 017 (100.0) NA NA
Incidence round outcomes:
 Positive screening test 2271 (6.8) 1910 (2.5) 2.86 (2.69 to 3.04) 3.00 (2.82 to 3.20)
 Immediate referral for colposcopy 495 (1.5) 1878 (2.4) 0.60 (0.54 to 0.66) 0.63 (0.57 to 0.70)
 Any colposcopy 373 (1.1) 1608 (2.1) 0.53 (0.47 to 0.59) 0.57 (0.51 to 0.64)
 CIN2+ 61 (0.2) 541 (0.7) 0.26 (0.29 to 0.34) 0.29 (0.22 to 0.38)
 CIN3+ 19 (0.1) 349 (0.5) 0.12 (0.08 to 0.20) 0.14 (0.09 to 0.23)
 Cervical cancer 0 15 (<0.1) NA NA
hrHPV=high risk human papillomavirus; LBC=liquid based cytology; NA=not applicable; CIN2+= cervical intraepithelial neoplasia grade 2 or worse; CIN3+= cervical intraepithelial neoplasia grade 3 
or worse.
*A further 2075 women screened with hrHPV testing in the prevalence round were screened with LBC in the incidence round, and 9434 women were screened with LBC in the prevalence round and 
with hrHPV testing in the incidence round.
†Adjusted for age, index of multiple deprivation decile, and laboratory.
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The coverage of the Cervical Screening Programme 
has decreased,17 and a switch to hrHPV testing should 
not exacerbate this. The screening processes and 
outcomes were monitored intensely during the pilot. 
We did not identify any serious incidents regarding 
women’s concerns or the practicability of large scale 
implementation of hrHPV testing. Adherence to 
colposcopy referral and early recall were both strong 
at 95% and 80%, respectively, and this will be an 
important element for achieving high sensitivity and 
cost effectiveness of hrHPV screening.18 Furthermore, 
early data from the incomplete incidence screening 
round shows a similar uptake of hrHPV testing and 
cytology screening. Uptake overall, however, remains 
lower in socioeconomically more deprived areas. 
Although not yet offered, self sampling facilitated 
by hrHPV testing represents a potential strategy to 
increase uptake.19
Strengths and weaknesses of this study
Two key strengths of this study are its large size and 
the early recall protocol for women with negative 
cytology. This is the largest report of using hrHPV 
testing in any organised national programme in the 
developed world.20-29 The largest report from Italy 
included 130 000 women screened with hrHPV 
testing and other reports were based on substantially 
smaller numbers of women or were limited to specific 
age groups, or both. We were able to identify even 
infrequent events with more accuracy in this large 
pilot, including the strongest data yet reported on 
outcomes from the subsequent incidence screening 
round(s). This confirms a very low incidence of 
cervical intraepithelial neoplasia grade 2 or worse 
and cervical cancer after the first round of screening 
with hrHPV testing. hrHPV was more prevalent in 
women screened in the English pilot than in most 
other studies because we included women as young 
as 24-29. This reiterates the importance of country 
specific data in informing a roll-out of hrHPV testing. 
Our study, which was conducted under conditions 
representative of a routine screening setting across 
England, has shown high clearance rates in women 
with negative cytology which avoids unnecessary 
colposcopy. It also showed that early recall of these 
women was adhered to by 80%, showing feasibility 
of this approach, ultimately leading to an uplift in the 
detection of cervical intraepithelial neoplasia grade 
2 or worse by approximately 50%. Despite expected 
real life issues such as non-participation in screening 
and protocol violation, hrHPV screening in England 
performed impressively, and as expected from the 
results of pivotal randomised trials.
A limitation of the pilot, for reasons of practicability, 
was that the selection of women for hrHPV screening 
was based predominantly on geographical area and 
not on individual randomisation. Age and deprivation 
differences between women undergoing hrHPV and 
cytology screening were relatively small, although 
statistically significant owing to large numbers. All 
comparisons of the two screening tests were adjusted 
for information that could be obtained from routine 
laboratory registrations, although some residual 
confounding probably remained. We were unable to 
determine the total number of colposcopies undertaken 
for investigation of screening abnormalities, although 
the data on the number of women with at least one 
colposcopy should be highly complete as they are used 
to identify women overdue for their recommended 
colposcopies. We were also unable to link with 
information on women’s full screening history and 
records of screening invitations, and screening 
coverage does differ between geographical areas.30 
All data were supplied by the laboratories and women 
could not be tracked if they had moved to another 
screening provider. Although completeness of follow-
up remained high, some underreporting of detected 
disease probably exists. All cases of cervical cancer 
in England are monitored through a formal audit,31 
and any cancers diagnosed after a negative hrHPV test 
result will be identified through that process.
Conclusion
This pilot undertaken under routine screening 
conditions has confirmed that primary hrHPV 
cervical screening is practicable on a large scale 
and confers approximately 40% greater sensitivity 
for cervical intraepithelial neoplasia grade 3 or 
worse and approximately 30% greater sensitivity for 
cervical cancer than primary liquid based cytology. 
This increased detection in a prevalence round was 
followed by a marked reduction in the incidence after 
three years, supporting an extension of the screening 
intervals.
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